View all Holmen SL publications in Google Scholar or PubMed
Selected Recent Publications:
Almazan J, Turapov T, Kircher DA, Stanley KA, Culver K, Medellin AP, Field MN, Parkman GL, Colman H, Coma S, Pachter JA, Holmen SL. Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastases. Cell Rep Med. 2025 Feb 18;6(2):101943. doi: 10.1016/j.xcrm.2025.101943. Epub 2025 Feb 7. PMID: 39922199.
Guerrieri RA, Fischer GM, Kircher DA, Joon AY, Cortez JR, Grossman AH, Hudgens CW, Ledesma DA, Lazcano R, Onana CY, Knighton BG, Kumar S, Hu Q, Gopal YNV, McQuade JL, Deng W, Haydu LE, Gershenwald JE, Lazar AJ, Tetzlaff MT, Holmen SL, Davies MA. Oxidative Phosphorylation (OXPHOS) Promotes the Formation and Growth of Melanoma Lung and Brain Metastases. bioRxiv [Preprint]. 2025 Jan 24:2025.01.23.633049. doi: 10.1101/2025.01.23.633049. PMID: 39896644; PMCID: PMC11785201.
Parkman GL, Holmen SL. A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies. J Cancer Immunol (Wilmington). 2024;6(3):92-99. doi: 10.33696/cancerimmunol.6.089. PMID: 39381117; PMCID: PMC11460539.
Parkman GL, Turapov T, Kircher DA, Burnett WJ, Stehn CM, O'Toole K, Culver KM, Chadwick AT, Elmer RC, Flaherty R, Stanley KA, Foth M, Lum DH, Judson-Torres RL, Friend JE, VanBrocklin MW, McMahon M, Holmen SL. Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression. Mol Cancer Ther. 2024 Mar 4;23(3):301-315. doi: 10.1158/1535-7163.MCT-23-0474. PMID: 37931033; PMCID: PMC10932877.
Amaravadi R, Aplin A, Herlyn M, Holmen S, White R, Villanueva J. 20th Anniversary of the Society for Melanoma Research: Celebrating two decades of progress in melanoma research. Pigment Cell Melanoma Res. 2023 Nov;36(6):562. doi: 10.1111/pcmr.13134. PMID: 37903735; PMCID: PMC11094691.
Orlow I, Sadeghi KD, Edmiston SN, Kenney JM, Lezcano C, Wilmott JS, Cust AE, Scolyer RA, Mann GJ, Lee TK, Burke H, Jakrot V, Shang P, Ferguson PM, Boyce TW, Ko JS, Ngo P, Funchain P, Rees JR, O'Connell K, Hao H, Parrish E, Conway K, Googe PB, Ollila DW, Moschos SJ, Hernando E, Hanniford D, Argibay D, Amos CI, Lee JE, Osman I, Luo L, Kuan PF, Aurora A, Gould Rothberg BE, Bosenberg MW, Gerstenblith MR, Thompson C, Bogner PN, Gorlov IP, Holmen SL, Brunsgaard EK, Saenger YM, Shen R, Seshan V, Nagore E, Ernstoff MS, Busam KJ, Begg CB, Thomas NE, Berwick M; InterMEL Consortium. InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. PLoS One. 2023 Apr 3;18(4):e0269324. doi: 10.1371/journal.pone.0269324. PMID: 37011054; PMCID: PMC10069769.
Karz A, Dimitrova M, Kleffman K, Alvarez-Breckenridge C, Atkins MB, Boire A, Bosenberg M, Brastianos P, Cahill DP, Chen Q, Ferguson S, Forsyth P, Glitza Oliva IC, Goldberg SB, Holmen SL, Knisely JPS, Merlino G, Nguyen DX, Pacold ME, Perez-Guijarro E, Smalley KSM, Tawbi HA, Wen PY, Davies MA, Kluger HM, Mehnert JM, Hernando E. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2022 Nov;35(6):554-572. doi: 10.1111/pcmr.13059. Epub 2022 Sep 1. PMID: 35912544; PMCID: PMC10171356.
Luo L, Shen R, Arora A, Orlow I, Busam KJ, Lezcano C, Lee TK, Hernando E, Gorlov I, Amos C, Ernstoff MS, Seshan VE, Cust AE, Wilmott J, Scolyer RA, Mann G, Nagore E, Funchain P, Ko J, Ngo P, Edmiston SN, Conway K, Googe PB, Ollila D, Lee JE, Fang S, Rees JR, Thompson CL, Gerstenblith M, Bosenberg M, Gould Rothberg B, Osman I, Saenger Y, Reynolds AZ, Schwartz M, Boyce T, Holmen S, Brunsgaard E, Bogner P, Kuan PF, Wiggins C, Thomas NE, Begg CB, Berwick M; InterMEL. Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study. Pigment Cell Melanoma Res. 2022 Nov;35(6):605-612. doi: 10.1111/pcmr.13058. Epub 2022 Aug 12. PMID: 35876628; PMCID: PMC9640183.
Parkman GL, Foth M, Kircher DA, Holmen SL, McMahon M. The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance. Exp Dermatol. 2022 Jan;31(1):43-56. doi: 10.1111/exd.14489. Epub 2021 Nov 9. PMID: 34717019; PMCID: PMC8724390.
Wang X, Haaland B, Hu-Lieskovan S, Colman H, Holmen SL. First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer Rep (Hoboken). 2021 Dec;4(6):e1419. doi: 10.1002/cnr2.1419. Epub 2021 Jun 17. PMID: 34137219; PMCID: PMC8714542.
Parkman GL, Kircher DA, Stehn CM, McMahon M, Holmen SL. Model-dependent outcomes: Sex as a biological variable in preclinical mouse models of melanoma. Pigment Cell Melanoma Res. 2021 May;34(3):655-658. doi: 10.1111/pcmr.12940. Epub 2020 Nov 11. PMID: 33098202; PMCID: PMC8052264.
Valiente M, Van Swearingen AED, Anders CK, Bairoch A, Boire A, Bos PD, Cittelly DM, Erez N, Ferraro GB, Fukumura D, Gril B, Herlyn M, Holmen SL, Jain RK, Joyce JA, Lorger M, Massague J, Neman J, Sibson NR, Steeg PS, Thorsen F, Young LS, Varešlija D, Vultur A, Weis-Garcia F, Winkler F. Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Res. 2020 Oct 15;80(20):4314-4323. doi: 10.1158/0008-5472.CAN-20-0291. Epub 2020 Jul 8. PMID: 32641416; PMCID: PMC7572582.
AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis
Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, Holmen SL (2019). Mol Cancer Res, 17(9), 1787-1800.
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA (2019). Cancer Discov, 9(5), 628-645.
Mutant IDH1 Promotes Glioma Formation In Vivo
Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL. Cell Rep (2018) 23:1553-1564.
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma
Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW. Melanoma Res (2017) 27:545-557
Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, Lo RS
Cancer Discovery (2017) doi:10.1158/2159-8290
HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss
Shin CH, Robinson JP, Sonnen JA, Welker AE, Yu DX, VanBrocklin MW, Holmen SL
Oncogene (2016) 2:311-329
AKT1 activation promotes development of melanoma metastases
Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL
Cell Reports (2015) 13:898-905
Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.
VanBrocklin MW, Robinson JP, Lastwika KJ, Khoury JD, Holmen SL
Pigment Cell Melanoma Res (2010) 23:531-41
Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.
Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL.
Oncogene (2010) 29:335-44